Company Overview and News
Almost after a year of conducting raids on German automakers, regulators of European Union have initiated an in-depth probe to determine whether a possible collusion between the top automakers has taken place to delay the development of vehicle emission technologies. Five German automakers facing investigation are Daimler AG (DDAIF - Free Report) , BMW AG (BAMXF - Free Report) and Volkswagen AG (VLKAY - Free Report) as well as its two brands i.
VLKAF DDAIF VLKAY
Last week witnessed the troubled German automakers facing regulatory probe. European Union regulators opened an in-depth investigation to find out whether there was a possible collusion between top automakers to impede the development of emission technologies. It will be investigated whether the companies decided not to compete with each other by developing catalytic reduction systems to curb pollution from gasoline or diesel-engine passenger cars.
CPRT AZO THO LB VLKAF GM AAP LAD VLKAY
Volkswagen AG (VLKAY - Free Report) intends to manufacture 10 million electric cars (e-cars) by utilizing its new modular MEB platform, per Reuters. This is in sync with this German auto giant’s target of starting the global mass production of e-cars toward the end of 2022. Per the news, this auto giant will build vehicles of 27 models, using the MEB — or modular electrification kit — at its plant in Zwickau, Germany, late 2019.
FOXF VLKAF MDPEB ALSN MDP VLKAY
Automobile sales in China, the biggest global auto market, have been declining in recent times. Vehicle sales in Chinese mainland declined for the second straight month in August due to economic malaise and the ongoing trade spat with Washington. According to data provided by China Association of Automobile Manufacturers (CAAM), in August, auto sales in China fell 3.8% year over year to 2.1 million.
VLKAF GM VLKAY
Recalls are rampant in the auto industry across the globe, with a steep rise noticed in recent years. A recall is issued when a vehicle or its parts do not comply with the stipulated safety standards or poses safety risks to passengers. In the event of a recall, manufacturers are required to sort out the problem through repair, replacement and refund or in extreme cases repurchase of the faulty vehicle.
VLKAF TM 7203 TYT DDAIF FCAU TOYOF VLKAY
Total's share price has performed well since the company was added to the Nest Egg Portfolio.
SGPEF WOPEF FLOW DIREN RDSB RDSA WRDEF ENGIY BINCY SGPEY MBSRF MS RYDAF BPOSY VLKAY BPOST LNAGF INTU BT.A RDS.B RDS.A MBSRY BTGOF CCRGF WPL WOPEY BPOSF BT PWOPY ENGQF RYDBF
2018-09-07 zacks - 1
A thriving economy and favorable job market are boosting consumers’ confidence in buying vehicles from a diverse range available in the market. With steady sales, the auto industry is witnessing a preference shift from passenger cars to sports utility vehicles (SUVs), pickup trucks and crossovers. Spacious vehicles like SUVs are a more striking option for consumers, thus, leading to a plunging demand for passenger cars.
VLKAF ALLY TM 7203 TYT FCAU TOYOF VLKAY
Four years after the go-ahead, the all-electric Mercedes SUV has finally been unveiled. Production begins in 2019 and will include deliveries to Germany, Europe and China.
The global automotive market continues to grow but demand in key markets is easing. A modest global economic outlook for 2018 and 2019 along with robust demand in some emerging markets in Asia has kept hopes alive for the industry amid growing trade tensions. Foreign automakers play a key role in the U.S. auto space. In fact, vehicles that are imported and those built by foreign manufacturers in the United States have a huge impact on the automotive industry.
VLKAF CHTR TM 7203 TYT TOYOF VLKAY
California and several other U.S. states are imposing new emissions laws and de-facto taxation to reduce gasoline/diesel car sales, while increasing electric car sales.
2018-09-02 seekingalpha - 1
Global electric car sales - US electric car market share hits a record 2.2% in July. Q2, 2018 EV sales up 77% YoY. Tesla moves to be number 1 globally.
RNSDF TM GELYF DTK NVDA GOOG 0175 AAPL GM FUTR MS INTC BIDU VLKAY GPV BCCMY TYT GELYY DDAIF TOYOF AUDVF GOOGL 0700 7203 QCOM APTV
2018-09-01 seekingalpha - 8
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
HIBB JWN DKS AVGO APRN PCB SODA AMC TMUS PDYPF AKCA JONE COUP SOLO REV MESA CZR LJPC VZ HEAR FCAU BRC MGM GCO FB ULTA IGT TM IRBT VCNX CTXR LB GMVHF MTCH DBX KS JNEEP AAPL USAK TSG ZAGG PRTY KSU DDS MRVL COOL HMC GBX TSCO DSKE MU DG WRK BYD LOW LRCX TXN CTRP TWX HA SKYW GNC RCL RH UAL PFCF AMZN TWTR CATO BKS VLKAY OSTK AAL BKE BBY GWRE MDLZ GME ON NSC NAV GOOGL QCOM HD XLNX CHDN CPB WDAY FND JBLU QSII WIMHY ALK ADBE MDXG GM GOGO CROX DAL CWH WIMHF F TECH PANW COST M SAVE WMH W S PEP URBN
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET